Compare CVS Health Corp (CVS) vs Caesars Entertainment Inc (CZR) Price & Performance

CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.

CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.

Caesars Entertainment (CZR) trades at $29.61, down 1.53% on the day, with a bearish technical signal and recent quarterly earnings misses. The company shows strong operating cash flow of $1.3 billion in 2025 but faces net losses and high debt levels. Recent news highlights a pending acquisition by Tilman Fertitta for $5.7 billion, which could reshape its future.

CZR presents a mixed outlook: low P/E and P/S ratios suggest value, but persistent losses and high leverage pose risks. The acquisition offers potential upside, yet execution and integration challenges remain. Investors should weigh the attractive valuation against fundamental weaknesses and market sentiment leaning cautious.